Bristol Myers Squibb (BMY) Stock Forecast & Price Target

Bristol Myers Squibb
Bull Case

Here are some ways that investors could benefit from investing in Bristol-Myers Squibb:

• Bristol-Myers Squibb recently reported strong second-quarter results, beating analyst expectations with earnings per share of $2.04 against a consensus estimate of $1.60 and revenue of $12.97 billion compared to the expected $11.74 billion, demonstrating robust operational performance and profitability with a net margin of 18.87%.
• The company offers an attractive income stream with a dividend yield of 3.91%, having recently paid a quarterly dividend of $0.63 per share, which provides a steady cash flow for investors while maintaining a payout ratio of 55.51% that leaves room for future growth.
• Bristol-Myers Squibb shares are currently trading at $63.53, which is below the consensus price target of $66.33 and the 52-week high of $68.64, suggesting potential upside for investors as the stock has recently hit new 52-week highs in August 2026.
• Positive pipeline developments, such as the successful mid-stage trial results for the experimental therapy arlocabtagene autoleucel in multiple myeloma, strengthen the company's long-term oncology growth prospects and support its valuation despite recent market volatility.
• Institutional investors are showing renewed confidence, with The Manufacturers Life Insurance Company increasing its position by 23.2% in the second quarter and other firms like Northwestern Mutual and KCM Investment Advisors also adding to their stakes, indicating broad market support for the stock.